Controversies in intravitreal triamcinolone acetonide use

International Ophthalmology Clinics

Volumn 45, Issue 4, 2005, Pages 133-141

  Sobrin, Lucia ^a   D'Amico, Donald J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIGLAUCOMA AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID; TRIAMCINOLONE ACETONIDE;

ADJUVANT THERAPY; CILIARY DISK; CORTICOSTEROID THERAPY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOPHTHALMITIS; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; STEROID THERAPY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY;

CHOROID DISEASES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; RETINAL DISEASES; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 27544469368     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000176353.56990.3b     Document Type: Review

References (36)

1. Florez J. Corticosteroids. In: Florez J, ed. Human Pharmacology. Barcelona: Masson; 2003.
2. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetate. Am J Ophthalmol. 1980;90:810-816.
3. Chandler DB, Rozakis G, de Juan E, et al. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol. 1985; 99:686-690.
4. Antoszyk AN, Gottlieb JL, Machemer R, et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993;231:34-40.
5. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996; 103:2099-2104.
6. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985;103:708-711.
7. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121: 458-465.
8. Penfold PL, Wong J, Gyory J, et al. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Exp Ophthalmol. 2001;29:188-192.
9. Nauck M, Karakiulakis G, Peruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
10. McCuen BW, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91:785-788.
11. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336-340.
12. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110: 681-686.
13. Massin P, Audren F, Erginay A, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: results of a prospective controlled trial. ARVO Abstract 2004; program 3463.
14. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24-27.
15. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging. 2003;34:386-390.
16. Wingate RJB, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27:431-432.
17. Kaushik S, Gupta V, Gupta A, et al. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004;137:758-760.
18. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-224.
19. Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye. 2004;18:361-364.
20. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
21. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-1282.
22. Sutter FKP, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-974.
23. Flynn HW, Moshfeghi AA, Scott IU, et al. Pseudohypopyon following intravitreal triamcinolone acetonide injection for cystoid macular edema. ARVO Abstract 2004; program 1046.
24. Parke DW. Editorial: intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol. 2003;136:918-919.
25. Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol. 2003; 121:271-273.
26. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423-429.
27. Furino C, Ferrari TM, Boscia F, et al. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina. 2003;23:771-776.
28. Kimura H, Kuroda S, Nagata M. Triamcinolone acetonide-assisted peeling of the internal limiting membrane. Am J Ophthalmol. 2004;137:172-173.
29. Fraser EA, Cheema RA, Roberts MA. Triamcinolone acetonide-assisted peeling of retinal internal limiting membrane for macular surgery. Retina. 2003;23:883-884.
30. Jonas JB, Sofker A, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2003;13:468-473.
31. Jonas JB, Sofker A, Hayler J, et al. Intravitreal crystalline triamcinolone acetonide as an additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy. Acta Ophthalmol Scand. 2003;81:663-665.
32. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667-673.
33. Danis RP, Ciulla T, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
34. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003;87:462-468.
35. Jonas JB, Akkoyun I, Budde W, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004;122:218-222.
36. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517-1525.